MD One Ventures & Randox launch Accelerator Randox for Builders

MD One Ventures, Europe’s first Defence and National Security Venture Capital team and Randox, a global diagnostics and healthcare company from the UK and Ireland, today announce the launch of Randox for Builders, a security and biotech incubator and accelerator for UK and European founders and their teams.

‍

Alongside investment, founders get instant access to a ready-made network of world-class scientific experts, R&D, and commercial resources. This combined support allows teams to focus on what they do best, while drawing on leading industry skills whenever they need them. Offering companies an asymmetric advantage, it provides growth support without taking equity.

At its core, Randox for Builders is about strengthening national resilience. The founders and innovations it will support are not just commercial opportunities, they are technologies that will shape the future security and health of the UK and its allies. By fast-tracking solutions with real-world impact, the incubator aims to ensure that the next generation of breakthrough capabilities is built, tested and deployed far earlier than traditional systems allow.

Selected founders and their startups will gain access to Randox’s global leadership in diagnostics and biotechnology, leveraging resources rarely accessible to early-stage ventures, including the below and more:

• Access to advanced laboratories & manufacturing facilities
• Clinical trials and validation
• Commercial partnerships
• Distribution channels
• Regulatory framework advice and support
• World leading resources for IP and Research
• Deeply established routes to market – B2B and B2C

Wil McManners, Co-founder of MD One Ventures commented:

“This is not a traditional accelerator, it’s a strategic partnership designed to de-risk and accelerate companies that solve national security and public health challenges. The access our founders receive to Randox’s infrastructure is literally a money can’t buy opportunity. We are looking to support world class founding teams that can deliver solutions to fundamental issues affecting our National Infrastructure, Health and ultimately, Security“.

Dr. Cecilia Fortugno, Vice President and Chief Operations Officer at Randox Biosciences and the Senior Technical Advisor for Randox for Builders said:

“For forty years, Randox has invested deeply in R&D to drive diagnostic and preventative healthcare. This program with MD Ones is a natural extension of that mission. By opening our technical infrastructure to the next generation of innovators, we are ensuring that the solutions to future health and security challenges are being built and scaled rapidly right now.”

The incubator has already started investing, with initial companies including; Untap Health, which delivers automated wastewater-based diagnostics and Airfinity, which provides a health intelligence and bio risk forecasting platform, integrating AI-driven simulations.

Claire Trant, CEO of Uptap added:

“For a fast-scaling company like Untap, partnering with Randox, an established global diagnostics leader, helps us bridge the ‘valley of death’ that often stalls breakthrough technologies. The MD One Randox for Builders programme is the kind of collaboration that de-risks growth, unlocks new markets, and positions us to lead the next generation of health infrastructure.”

Rasmus Bech Hansen, CEO and co-founder of Airfinity shared:

“We are really excited to take part in the Randox for Builders program. Randox’s millions of daily data points, one of the scarcest resources in life sciences, combined with Airfinity’s analytics technology platform, presents an opportunity to accelerate drug development, strengthen health security and generate new insights for the wider health system.

Founders who are seeking ways to deliver a National Security Advantage to the UK and it’s Allies, can apply now here.

‍